Results 161 to 170 of about 141,956 (266)

Histiocytosis development and clinical variation through the lens of genomics

The Journal of Pathology, EarlyView.
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps, Astrid GS van Halteren, Tom van Wezel, Pancras CW Hogendoorn   +3 more
wiley   +1 more source

Mosaic <i>TP53</i> pathogenic variant in early-onset breast cancer: a case report. [PDF]

Front Oncol
Greco L, Miggiano C, Dal Buono A, Barile M, Borroni R, Rodà G, Santoro A, Repici A, Cavalli P, Bianchi P.   +9 more
europepmc   +1 more source

TP53 Antibody [PDF]

, 2020
openaire   +1 more source

Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancer

The Journal of Pathology, EarlyView.
Abstract Recently, we suggested the combination of chemotherapy and P2RX4 inhibition as a promising novel therapeutic approach for P2RX4‐expressing epithelial tumors to prevent paracrine resistance. Here, we aimed to assess whether determining P2RX4 expression status in colorectal and pancreatic cancer patients would allow stratification of potentially
Christoph Steup, Julian Dosch, Christopher Dietz‐Fricke, Sara Khosraviseftejani, Esther Engel, Adalbert F de Valk, Dominic Menger, Patrick Welker, Peter J Wild, Kilian B Kennel, Maja Kantlehner, Paul K Ziegler, Florian R Greten   +12 more
wiley   +1 more source

Clinical significance of circulating tumor DNA monitoring based on TP53 mutation in high-grade serous ovarian cancer patients. [PDF]

Transl Cancer Res
Jung H, Kang OJ, Lee YJ, Kang SW, Lee MS, Lee SW, Kim YM.   +6 more
europepmc   +1 more source

Enabling Variant Proteogenomic Assay Development Through a Peptide Target Selection Pipeline and Web Application

PROTEOMICS, EarlyView.
ABSTRACT The quantification of key protein variants can guide precision oncology to enable better identification of driver mutations. Bottom‐up assays infer parent protein levels through the quantification of surrogate peptides. Assay methods designed for absolute quantification of protein variants, such as multiple reaction monitoring mass ...
Constantinos Blidjios, Pallab Bhowmick, Vincent R. Richard, Yassene Mohammed, Christoph H. Borchers   +4 more
wiley   +1 more source

Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts. [PDF]

Ann Hematol
Park S, Kim SA, Kim S, Kim SY, Lee JY, Byun JM, Hwang SM, Lee JO, Koh Y, Hong J, Chang YH, Kim HK, Bang SM, Kim I, Yoon SS, Shin DY.   +15 more
europepmc   +1 more source

A Large Pigmented Lesion on the Abdomen of a Woman

JEADV Clinical Practice, EarlyView.
Ángel Fernández‐Camporro, Julián José Ahijado‐González, Eva Miranda‐Martínez   +2 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Network Pharmacology, Molecular Docking and Dynamics Simulation Reveal the Anti-Colitis Mechanism of <i>Smilax glabra</i> Roxb. [PDF]

Clin Exp Gastroenterol
Cui Y, Hu J, Li Y, Tong Y, Shen H.
europepmc   +1 more source